Giraldi T, Sava G, Zorzet S, Perissin L, Piccini P
Anticancer Res. 1987 May-Jun;7(3 Pt B):343-6.
The cellular levels of cathepsin B-like cysteine proteinases have been determined in a panel of transplantable mouse leukemias possessing a different potential to metastatize to the liver after i.p. implantation. The higher enzymatic activity observed in L1210 leukemic cells matches their higher capacity for hepatic infiltration. No significant difference is observed for TLX5 lymphoma and P388 leukemia, in spite of their different liver invasiveness, and their enzymatic levels do not significantly differ from that of the non-invasive Ehrlich ascitic carcinoma. The in vivo administration of the antimetastatic drugs ICRF159 and DM-COOK, or of the cytotoxic drugs cyclophosphamide, cisplatin, CCNU and GANU, does not cause a pattern of enzyme inhibition matching the tumor metastatic potential and the increase in life-span of the treated tumor bearing mice, indicating that the inhibition of cathepsin B-like cysteine proteinase is not involved in either their cytotoxic or their antimetastatic action.
已测定了一组可移植的小鼠白血病细胞中组织蛋白酶B样半胱氨酸蛋白酶的细胞水平，这些白血病细胞在腹腔注射植入后向肝脏转移的潜力各不相同。在L1210白血病细胞中观察到的较高酶活性与其较高的肝浸润能力相匹配。尽管TLX5淋巴瘤和P388白血病的肝侵袭性不同，但未观察到显著差异，并且它们的酶水平与非侵袭性艾氏腹水癌的酶水平无显著差异。体内给予抗转移药物ICRF159和DM-COOK，或细胞毒性药物环磷酰胺、顺铂、CCNU和GANU，不会导致与肿瘤转移潜力和治疗的荷瘤小鼠寿命延长相匹配的酶抑制模式，这表明组织蛋白酶B样半胱氨酸蛋白酶的抑制与其细胞毒性或抗转移作用均无关。
